Abstract
This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 700-704 |
| Number of pages | 5 |
| Journal | Journal of Pediatric Hematology/Oncology |
| Volume | 29 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemotherapy
- Extraocular disease
- Orbital involvement
- Retinoblastoma
- Survival
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
Cite this
The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. / Antoneli, Célia Beatriz Gianotti; Ribeiro, Karina B.; Rodriguez-Galindo, Carlos; Soares, Fernando A.; Arias, Victor A.; Novaes, Paulo E.R.S.; Chojniak, Martha M.; Malogolowkin, Marcio.
In: Journal of Pediatric Hematology/Oncology, Vol. 29, No. 10, 01.10.2007, p. 700-704.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement
AU - Antoneli, Célia Beatriz Gianotti
AU - Ribeiro, Karina B.
AU - Rodriguez-Galindo, Carlos
AU - Soares, Fernando A.
AU - Arias, Victor A.
AU - Novaes, Paulo E.R.S.
AU - Chojniak, Martha M.
AU - Malogolowkin, Marcio
PY - 2007/10/1
Y1 - 2007/10/1
N2 - This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.
AB - This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.
KW - Chemotherapy
KW - Extraocular disease
KW - Orbital involvement
KW - Retinoblastoma
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=35148814440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35148814440&partnerID=8YFLogxK
U2 - 10.1097/MPH.0b013e31814fb7ea
DO - 10.1097/MPH.0b013e31814fb7ea
M3 - Article
C2 - 17921851
AN - SCOPUS:35148814440
VL - 29
SP - 700
EP - 704
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
SN - 1077-4114
IS - 10
ER -